Lactic acid bacteria composition for preparing fermented products
By mutating key genes in Streptococcus thermophilus strains, the fermentation capacity and acidification rate of galactose were enhanced, solving the problems of sweetness and texture properties in fermented dairy products. This enabled rapid acidification and improved texture properties, meeting the needs of the food industry.
Patent Information
- Application Number
- CN202280012710.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2021-07-13
- Filing Date
- 2022-02-23
- Publication Date
- 2026-11-10
- Estimated Expiration
- 2042-02-23
AI Technical Summary
Existing fermented dairy products face challenges in meeting consumers' demand for natural sweetness, especially since Streptococcus thermophilus strains have a slow acidification rate when fermenting galactose, affecting the product's sweetness and texture properties, and artificial sweeteners pose health risks.
To develop novel *Streptococcus thermophilus* strains, by mutating the manM gene encoding glucose/fructose subunit IIC, the galK gene encoding galactokinase, the pgm gene encoding glucose phosphate mutase, the galR gene encoding galactose operon repressor, and the glcK gene encoding glucokinase, the fermentation capacity and acidification rate of galactose can be improved, thereby enhancing textural properties.
This technology enables rapid acidification of thermophilic streptococcal strains during fermentation, improving product sweetness and texture, shortening fermentation time, and meeting the economic needs of the food industry.
Smart Images

Figure CN116828988B_ABST
Abstract
Description
[0001] Technical Field of the Invention
[0002] This invention relates to one or more novel thermophilic streptococci ( Streptococcus thermophilus The invention relates to compositions of *Streptococcus thermophilus* strains, and the use of said compositions in the production of fermented products such as dairy products having increased sweetness. Therefore, the invention also relates to novel *Streptococcus thermophilus* strains. Background of the Invention
[0003] Purely fermented dairy products have a sour taste because lactic acid bacteria convert lactose into lactic acid during the fermentation process. Therefore, these products are usually sweetened by adding fruits, honey, sugar, or artificial sweeteners to meet consumers' demand for sweetness.
[0004] The food industry has a growing demand for low-calorie sweetened foods to help combat the prevalence of overweight and obesity over the past 20 years. Sweetness, generally considered a pleasurable sensation, is produced by the presence of sugars and other substances. The perception of sugar varies considerably. Using sucrose as a reference of 100, lactose has a sweetness level of 16, galactose 32, and glucose 74 (God-shall (1988). Food Technology 42(II): 71-78). Therefore, glucose is considered more than four times sweeter than lactose while still having roughly the same calorie level.
[0005] In fermented foods, sugar is often replaced by sweeteners such as aspartame, acesulfame potassium, sucralose, and saccharin, which provide sweetness with less calorie intake. However, the use of artificial sweeteners can lead to off-flavors, and some studies have shown that consuming artificial sweeteners is accompanied by disadvantages such as increased hunger, allergies, and cancer. This has led consumers to prefer fermented dairy products containing only natural sweeteners or preferably none at all. Therefore, developing fermented dairy products with high natural (intrinsic) sweetness has become a particular challenge.
[0006] The acidity of fermented dairy products largely depends on the lactic acid bacteria present and the process parameters used to prepare them.
[0007] Because the disaccharide lactose is the main carbon source in milk, its fermentation in lactic acid bacteria has been extensively studied. In many species, lactose is broken down into glucose and galactose by β-galactosidase after ingestion. Glucose is phosphorylated to glucose-6-phosphate by glucokinase and fermented by most lactic acid bacteria via the Embden-Meyerhof-Parnas pathway (glycolysis).
[0008] Streptococcus thermophilus ( S. thermophilusLactobacillus is one of the most widely used lactic acid bacteria for commercial thermophilic milk fermentation, where it is typically used as part of a mixed starter culture, with other components being Lactobacillus (…). Lactobacillus ) species, such as Lactobacillus delbrueckii subsp. bulgaricus used in yogurt ( Lactobacillus delbrueckii subsp. bulgaricus Lactobacillus bulgaricus ( L. bulgaricus ()) or Lactobacillus helveticus used in Swiss cheese ( Lactobacillus helveticus ( L. helveticus )).
[0009] Many countries' legal definitions of yogurt require the use of *Streptococcus thermophilus* in conjunction with *Lactobacillus bulgaricus*. Other countries require *Streptococcus thermophilus* in conjunction with *Lactobacillus acidophilus*. L. acidophilus Used together. All species produce adequate amounts of acetaldehyde, which is an important flavor component in yogurt.
[0010] Lactose and sucrose are more readily fermented by *Streptococcus thermophilus* than their constituent monosaccharides. When *Streptococcus thermophilus* is used in the presence of excess galactose, only the glucose portion of the lactose molecule is fermented, and galactose accumulates in fermented dairy products. In yogurt where fermentation is limited by high acid concentrations, free galactose remains, whereas the free galactose produced in the early stages of Swiss cheese production is later fermented by *Lactobacillus helveticus*.
[0011] However, some researchers have reported galactose-fermenting strains of Streptococcus thermophilus (Hutkins et al. (1986) J. Dairy Sci. 69(1): 1-8; Vaillancourt et al. (2002) J. Bacteriol.184(3); 785-793) and described methods for obtaining galactose-fermenting Streptococcus thermophilus strains in WO2011 / 026863 (Chr. Hansen)). Subsequently, Chr. Hansen published several papers on other galactose-fermenting strains.
[0012] To meet the requirements of the food industry, it has become meaningful to develop new strains, particularly thermophilic streptococcal strains, which provide greater natural sweetness (intrinsic sweetness) through glucose excretion without additional heat directly entering the fermentation product. Galactose-producing strains have been observed to typically exhibit slower acidification profiles, thus the industry needs rapid acidification strains capable of fermenting galactose or those well-suited to galactose-fermenting strains. Rapid acidification can shorten fermentation time, thereby improving process economics and / or the interaction between microbial species. Texture properties can also be affected by galactose-fermenting strains, and therefore there is a desire to develop galactose-fermenting strains with improved texture properties or strains with improved texture properties that are well-suited to galactose-fermenting strains. Invention Overview
[0013] This invention achieves the above-mentioned objectives, and in particular, this invention relates to compositions comprising one or more novel galactose-fermenting strains of *Streptococcus thermophilus*. The novel galactose-fermenting *Streptococcus thermophilus* strains contain IIC encoding glucose / fructose subunits. manM Genes encoding galactokinase galK Genes encoding glucose-phosphotransferase pgm Genes and / or genes encoding galactose galR One or more mutations in the gene. In addition to being able to ferment galactose, these novel Streptococcus thermophilus strains exhibit rapid acidification, acidification to low pH, and / or improved textural properties during fermentation when used alone and / or in combination with other Streptococcus thermophilus strains and / or Lactobacillus strains.
[0014] Therefore, in one aspect, the present invention relates to compositions comprising a *Streptococcus thermophilus* strain having a mutation in one or more genes selected from the group consisting of: (a) Encoding PTS mannose / glucose / fructose subunit IIC manM The gene is located at position 169 in SEQ ID NO.1; (b) Encoding galactokinase galK The gene is located at position 139 in SEQ ID NO.3; (c) Encoding phosphoglucomutase pgm The gene is located at position 490 corresponding to SEQ ID NO. 5 or 13; (d) Encoding glucose-phosphotransmutase pgm The gene is located at position 726 in SEQ ID NO.7; (e) Encoding galactose operon repressors galR The gene is located at position 82 corresponding to SEQ ID NO.9; and (f) Encoding glucokinase glcK The gene is located at position 805 in SEQ ID NO.11.
[0015] Another aspect of the invention relates to a method for producing fermentation products, comprising using a thermophilic streptococcal strain having a mutation in one or more genes selected from the group consisting of: (a) Encoding PTS mannose / glucose / fructose subunit IIC manM The gene is located at position 169 in SEQ ID NO.1; (b) Encoding galactokinase galK The gene is located at position 139 in SEQ ID NO.3; (c) Encoding phosphoglucomutase pgm The gene is located at position 490 corresponding to SEQ ID NO. 5 or 13; (d) Encoding glucose-phosphotransmutase pgm The gene is located at position 726 in SEQ ID NO.7; (e) Encoding galactose operon repressors galR The gene is located at position 82 corresponding to SEQ ID NO.9; and (f) Encoding glucokinase glcK The gene is located at position 805 in SEQ ID NO. 11. Or the composition according to the present invention.
[0016] Therefore, one aspect of the present invention relates to fermentation products obtained by the method of the present invention.
[0017] Furthermore, one aspect of the present invention relates to fermentation products comprising a thermophilic streptococcal strain having a mutation in one or more genes selected from the group consisting of: (a) Encoding PTS mannose / glucose / fructose subunit IIC manM The gene is located at position 169 in SEQ ID NO.1; (b) Encoding galactokinase galK The gene is located at position 139 in SEQ ID NO.3; (c) Encoding phosphoglucomutase pgm The gene is located at position 490 corresponding to SEQ ID NO. 5 or 13; (d) Encoding glucose-phosphotransmutase pgm The gene is located at position 726 in SEQ ID NO.7; (e) Encoding galactose operon repressors galR The gene is located at position 82 corresponding to SEQ ID NO.9; and (f) Encoding glucokinase glcK The gene is located at position 805 in SEQ ID NO.11.
[0018] Another aspect of the invention relates to the use of one or more thermophilic streptococcal strains for the manufacture of fermentation products, said thermophilic streptococcal strains having mutations in one or more genes selected from the group consisting of: (a) Encoding PTS mannose / glucose / fructose subunit IIC manM The gene is located at position 169 in SEQ ID NO.1; (b) Encoding galactokinase galK The gene corresponds to position 139 in SEQ ID NO.3; (c) Encoding phosphoglucomutase pgm The gene corresponds to position 490 in SEQ ID NO. 5 or 13; (d) Encoding glucose-phosphotransmutase pgm The gene is located at position 726 in SEQ ID NO.7; (e) Encoding galactose operon repressors galR The gene is located at position 82 corresponding to SEQ ID NO.9; and (f) Encoding glucokinase glcK The gene is located at position 805 in SEQ ID NO.11.
[0019] Importantly, one aspect of the invention relates to thermophilic streptococcal strains having mutations in one or more genes selected from the group consisting of: (a) Encoding PTS mannose / glucose / fructose subunit IIC manM The gene corresponds to position 169 in SEQ ID NO.1; (b) Encoding galactokinase galK The gene is located at position 139 in SEQ ID NO.3; (c) Encoding phosphoglucomutase pgm The gene is located at position 490 corresponding to SEQ ID NO. 5 or 13; (d) Encoding glucose-phosphotransmutase pgm The gene is located at position 726 in SEQ ID NO.7; (e) Encoding galactose operon repressors galR The gene is located at position 82 corresponding to SEQ ID NO.9; and (f) Encoding glucokinase glcKThe gene is located at position 805 in SEQ ID NO.11. Brief description of the attached figures
[0020] Figure 1 Lactic acidification curves of the parent plants of DSM 33762 and DSM 33762.
[0021] Figure 2 Lactic acidification curve of DSM 33720.
[0022] Figure 3 Progress in the adaptive laboratory evolution of strain DSM 33719.
[0023] Figure 4 Lactic acidification curves of the parent plants of DSM 33719 and DSM 33719. Invention Details
[0024] Before outlining the invention in more detail, a set of terms and conventions are defined: The term "genus" refers to the genus as defined on the website: www.ncbi.nlm.nih.gov / taxonomy. As used herein, a bacterial "strain" refers to a bacterium that remains genetically unchanged during growth or reproduction. This includes many identical bacteria.
[0025] In this context, the term "mutant strain" should be understood as a strain derived from or capable of being derived from the strains of the present invention through, for example, genetic engineering, radiation, and / or chemical treatment. Preferred mutant strains are functionally equivalent mutants, such as those having properties substantially the same as or improved upon their source strain (e.g., texture, shear stress, viscosity, gel hardness, mouthfeel, flavor, post-acidification, acidification rate, and / or phage robustness). Such mutant strains are part of the present invention. Specifically, the term "mutant strain" refers to strains obtained by subjecting the strains of the present invention to any conventionally used mutagenesis treatment (including chemical mutagens such as ethanemethanesulfonate (EMS) or N-methyl-N'-nitro-N-nitroguanidine (NTG), UV light treatment), or spontaneously generated mutant strains. The mutant strain may have undergone several mutagenesis treatments (a single treatment should be understood as one mutagenesis step, followed by a screening / selection step), but currently it is preferred to perform no more than 20, 10, or 5 treatments (or screening / selection steps). In the currently preferred mutant strains, less than 5%, 1%, or even less than 0.1% of nucleotides in the bacterial genome are replaced by another nucleotide or are deleted compared to the parent strain. As will be apparent to those skilled in the art, the mutant strain of the present invention can also be the parent strain.
[0026] In this context, the term "variant strain" should be understood as a strain functionally equivalent to the strains of the present invention, for example, having substantially the same or improved properties or characteristics (e.g., texture, acidification rate, viscosity, gel hardness, mouth coating, flavor, post-acidification, and / or phage robustness). Such variant strains, which can be identified using appropriate screening techniques, are part of the present invention.
[0027] For the purposes of this invention, the Needleman-Wunsch algorithm (Needleman and Wunsch (1970) J.Mol. Biol. 48: 443-453), preferably version 3.0.0 or higher, implemented in the Needle program of the EMBOSS software package (EMBOSS: The European Molecular Biology Open Software Suite, Rice et al. (2000) Trends in Genetics 16: 276-277), is used to determine the degree of identity between two amino acid sequences. Optional parameters used are a vacancy opening penalty of 10, a vacancy extension penalty of 0.5, and an EBLOSUM62 (EMBOSS version of BLOSUM62) substitution matrix. The Needle output labeled “Longest Identity” (obtained using the -no brief option) is used as the identity percentage and calculated as follows: (identical residues x 100) / (length of the alignment portion - total number of vacancies in the alignment portion) In this specification, conventional one-letter and three-letter codes for amino acid residues are used. For ease of reference, amino acid changes in mutants and variants of the present invention are described using the following nomenclature: amino acid residue in the parent enzyme; position; substituted amino acid residue. According to this nomenclature, for example, replacing the alanine residue at position 20 with a glycine residue is represented as Ala20Gly or A20G. The deletion of alanine at the same position is represented as Ala20. Or A20 The insertion of an extra amino acid residue (e.g., glycine) is represented as Ala20AlaGly or A20AG. The deletion of a continuous sequence of amino acid residues (e.g., alanine at position 20 through glycine at position 21) is represented as DELTA(Ala20-Gly21) or DELTA(A20-G21). When the parent enzyme sequence contains a deletion compared to the enzyme sequence used for numbering, an insertion at such a position (e.g., a deleted alanine at position 20) is represented as... 20Ala or 20A. Multiple mutations are separated by a plus sign or a forward slash. For example, two mutations at positions 20 and 21, replacing alanine and glutamic acid with glycine and serine respectively, are represented as A20G+E21S or A20G / E21S. When an amino acid residue at a given position is replaced by two or more optional amino acid residues, these residues are separated by a comma or a forward slash. For example, alanine at position 30 being replaced by glycine or glutamic acid is represented as A20G,E or A20G / E, or A20G,A20E. When this document identifies a suitable position for modification without specifying any particular modification, it should be understood that any amino acid residue can replace the amino acid residue present at that position. Therefore, for example, when a modification of alanine at position 20 is mentioned without specific details, it should be understood that alanine can be omitted or replaced by any other amino acid residue (i.e., any one of R, N, D, C, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y, V).
[0028] In the context of this invention, gene mutation (gene mutation) should be understood as an alteration in the nucleotide sequence of an organism's genome that results in a change in the organism's phenotype, wherein the alteration can be a nucleotide deletion, substitution of one nucleotide by another, insertion, or frameshift. In the context of this invention, deletion should be understood as a gene mutation that removes one or more nucleotides from the nucleotide sequence of an organism's genome; insertion should be understood as the addition of one or more nucleotides to the nucleotide sequence; substitution (or point mutation) should be understood as a gene mutation in which one nucleotide in the nucleotide sequence is replaced by another nucleotide; frameshift should be understood as a gene mutation caused by the insertion or deletion of multiple nucleotides in the nucleotide sequence that are not divisible by 3, thus altering the reading frame and resulting in a translation completely different from the original reading frame; introduction of a stop codon should be understood as a point mutation in the DNA sequence that causes premature termination of the codon; inhibition of substrate binding of the encoded protein should be understood as any mutation in the nucleotide sequence that causes a change in the protein sequence responsible for preventing the substrate from binding to the catalytic site of the protein. Furthermore, knockout mutants should be understood as gene mutations that result in gene removal or deletion, such as the removal or deletion of an entire gene or an entire open reading frame from the organism's genome.
[0029] In this specification, the use of standard single-letter codes for nucleotides follows a similar principle to the amino acid nomenclature described above.
[0030] Algorithms used for aligning sequences and determining the degree of sequence identity between them are well known in the art. For the purposes of this invention, the nucleotide sequence alignment method provided by the National Center for Biotechnology Information (NCBI) at https: / / blast.ncbi.nlm.nih.gov using standard parameters can be used.
[0031] Measure the acidification curve as disclosed in Example 1.
[0032] Measure the shear stress as disclosed in Example 4.
[0033] For Lactobacillus strains, the term "CFU" refers to colony-forming units, determined by growth (colony formation) on MRS agar plates after incubation at 37°C under anaerobic conditions for 3 days. The composition (g / L) of MRS agar is as follows: Bacto shows peptone 3: 10.0 Bacto Beef Extract: 10.0 Bacto yeast extract: 5.0 Dextran: 20.0 Sorbitol monooleate complex: 1.0 Ammonium citrate: 2.0 Sodium acetate: 5.0 Magnesium sulfate: 0.1 Manganese sulfate: 0.05 Dipotassium hydrogen phosphate: 2.0 Bacto agar: 15.0g Milli-Q water: 1000 ml.
[0034] Adjust the pH to 5.4 or 6.5: Add Lactobacillus rhamnosus ( L. rhamnosus ), Lactobacillus casei ( L. casei ) and Lactobacillus casei ( L. paracasei The pH was adjusted to 6.5. For all other Lactobacillus species, the pH was adjusted to 5.4. In particular, the pH of *Lactobacillus delbrueckii* subsp. bulgaricus, *Lactobacillus acidophilus*, and *Lactobacillus helveticus* was adjusted to 5.4. The pH of *Lactobacillus rhamnosus*, *Lactobacillus casei*, and *Lactobacillus paracasei* was adjusted to 6.5.
[0035] For Streptococcus thermophilus, the term "CFU" refers to a colony-forming unit determined by growth (colony formation) on M17 agar plates after incubation at 37°C for 3 days under anaerobic conditions. The composition (g / L) of M17 agar is as follows: Tryptone: 2.5 g Meat pepsin digest: 2.5 g Papain digest of soybean flour: 5.0 g Yeast extract: 2.5 g Meat extract: 5.0 g Lactose: 5.0 g Sodium glycerophosphate: 19.0 g Magnesium sulfate heptahydrate: 0.25 g Ascorbic acid: 0.5 g Agar: 15.0 g Milli-Q water: 1000 ml.
[0036] Adjust the pH to a final pH of 7.1 ± 0.2 (25°C). As used herein, the term "mutation inactivating glucokinase protein" refers to a mutation that results in an "inactivated glucokinase protein," meaning a glucokinase protein that, if present in a cell, cannot perform its normal function, or a mutation that prevents the formation of glucokinase protein or leads to its degradation. In particular, compared to a functional glucokinase protein, an inactivated glucokinase protein is a protein that cannot promote glucose phosphorylation to glucose-6-phosphate or promotes glucose phosphorylation to glucose-6-phosphate at a significantly reduced rate. Compared to genes encoding functional glucokinase proteins, genes encoding inactivated glucokinase proteins contain mutations in the gene's open reading frame (ORF), said mutations may include, but are not limited to, deletions, frameshift mutations, the introduction of stop codons or resulting amino acid substitutions, mutations that alter the functional properties of the protein, or promoter mutations that reduce or eliminate gene transcription or translation.
[0037] The term “functional glucokinase protein” as used in this article refers to a glucokinase protein that, if present in cells, promotes the phosphorylation of glucose to glucose-6-phosphate.
[0038] As used in this article, “mutant bacteria” or “mutant strain” refers to naturally occurring (spontaneous, naturally occurring) mutant bacteria or induced mutant bacteria whose genome (DNA) contains one or more mutations not present in wild-type DNA. “Induced mutant strain” is a bacterium in which the mutation is induced by human intervention (e.g., treatment with chemical mutagens, UV, or gamma radiation). In contrast, “spontaneous mutant strains” or “naturally occurring mutant strains” have not been induced by humans. The mutant bacteria in this article are non-GMO (unmodified genetically modified organisms), i.e., not modified by recombinant DNA technology.
[0039] As used herein, the term "mutation that reduces glucose transport into cells" refers to a mutation in the gene encoding a protein involved in glucose transport, which leads to the accumulation of glucose in the cellular environment. Glucose levels in culture media of Streptococcus thermophilus strains can be readily measured using methods known to those skilled in the art.
[0040] The term “mutation that inactivates glucose transporters” as used in this article refers to mutations that result in “inactivated glucose transporters,” that is, glucose transporters that, if present in cells, cannot perform their normal functions, as well as mutations that prevent the formation of glucose transporters or cause glucose transporter degradation.
[0041] The term “functional glucose transporter” as used in this article refers to a glucose transporter that, if present in a cell, facilitates the transport of glucose across the cell membrane.
[0042] In the context of this invention, the term "glucose deficiency" is used to characterize lactic acid bacteria (LAB) that have partially or completely lost the ability to use glucose as a source of cell growth or to maintain cell viability. Such defects in glucose metabolism may be caused, for example, by gene mutations that inhibit or inactivate the expression or activity of glucokinase proteins and / or glucose transporters responsible for glucose uptake.
[0043] Lactose-deficient lactobacilli (LABs) may increase glucose concentration in the culture medium when grown on a lactose-based carbohydrate source. This glucose elevation is caused by glucose secretion from the lactose-deficient LABs. The increase in glucose concentration in the culture medium can be determined by HPLC analysis, for example, using Dionex CarboPac PA 20 3. 150 mm column (Thermo Fisher Scientific, product number 060142).
[0044] In the context of this invention, the term "glucose-positive" is used to characterize a LAB that partially or completely retains the ability to use glucose as a source of cell growth or to maintain cell viability.
[0045] The inventors have surprisingly identified numerous thermophilic streptococcal strains that meet industrial requirements. When applied as part of a mixed culture in a dairy matrix, one or more novel galactosomal fermentation strains exhibit, for example, improved rheological properties (e.g., texture). Similarly, when applied alone or as part of a mixed culture in a dairy matrix, one or more novel galactosomal fermentation strains exhibit, for example, improved acidification characteristics (e.g., acidification rate) (Examples 1-2). Furthermore, one or more novel galactosomal fermentation strains are able to acidify the fermentation medium to a lower pH than their parent strain, as seen, for example, in Example 2.
[0046] Novel thermophilic streptococcal strains can be used in dairy cultures, such as yogurt cultures, to achieve improved sweetness and rheological parameters, such as the shear stress of the finished product. Rheology is closely related to the sensory quality of a product, and therefore the interaction between rheology and the taste of the finished product is crucial. Furthermore, novel thermophilic streptococcal strains may accelerate fermentation time due to their improved acidification profiles.
[0047] composition Therefore, one aspect of the present invention relates to a composition comprising a *Streptococcus thermophilus* strain having a mutation in one or more genes selected from the group consisting of: (a) IIC encoding PTS mannose / glucose / fructose subunits manM The gene is located at position 169 in SEQ ID NO.1; (a) Encoding galactokinase galK The gene is located at position 139 in SEQ ID NO.3; (b) Encoding phosphoglucose mutase pgm The gene is located at position 490 corresponding to SEQ ID NO. 5 or 13; (c) Encoding phosphoglucose mutase pgm The gene is located at position 726 in SEQ ID NO.7; (d) Encoding galactose operon repressors galR The gene is located at position 82 corresponding to SEQ ID NO.9; and (b) Encoding glucokinase glcK The gene is located at position 805 in SEQ ID NO.11.
[0048] In one implementation, the mutation causes a change in the protein encoded by a selection of the following groups: a) PTS mannose / glucose / fructose subunit IIC, at position 57 corresponding to SEQ ID NO 2; b) Galactokinase, at position 47 corresponding to SEQ ID NO 4; c) phosphogluconomutase, at position 242 corresponding to SEQ ID NO 6 or 14; d) phosphogluconomutase, at position 164 corresponding to SEQ ID NO 8; e) The galactose operon repressor, at position 28 corresponding to SEQ ID NO 10; and f) Glucokinase, at position 268 corresponding to SEQ ID NO 12; In a further implementation, the mutation is: (a) Substitution from C to T at position 169 in SEQ ID NO.1; (b) Substitution from G to A at position 139 in SEQ ID NO.3; (c) Substitution from A to C at position 726 corresponding to SEQ ID NO. 5 or 13; (d) Substitution from C to T at position 490 in SEQ ID NO.7; (e) Substitution from C to T at position 82 in SEQ ID NO. 9; and (f) Substitution from G to T at position 805 in SEQ ID NO.11.
[0049] In yet another implementation, the changes in the encoded protein are: (a) Pro is replaced by Leu at position 57 in SEQ ID NO 2; (b) At position 47 in SEQ ID NO 4, Ile is replaced by Val; (c) Glu is replaced by Asp at position 242 in SEQ ID NO 6 or 14; (d) Pro is replaced by Ser at position 164 in SEQ ID NO 8; (e) Leu is replaced by Phe at position 28 in SEQ ID NO 10; and (f) Gly is replaced by Cys at position 268 in SEQ ID NO 12.
[0050] In one specific implementation, the thermophilic streptococcus strain contains the following mutations: (a) Substitution from C to T at position 169 in SEQ ID NO.1; substitution from nucleotide G to A at position 139 in SEQ ID NO.3; and substitution from nucleotide A to C at position 726 in SEQ ID NO.5 or 13; (b) A substitution from C to T at position 490 corresponding to position 490 in SEQ ID NO. 5 or 13 and a substitution from nucleotide C to T at position 82 corresponding to position 82 in SEQ ID NO. 7; or (c) Substitution from G to T at position 805 in SEQ ID NO.9.
[0051] In terms of amino acid profiles, it can be assumed that thermophilic streptococcal strains contain the following variations in the encoded proteins: (a) Pro is replaced by Leu at position 57 in SEQ ID NO 2; Ile is replaced by Val at position 47 in SEQ ID NO 4; and Glu is replaced by Asp at position 242 in SEQ ID NO 6 or 14; (b) Pro is replaced by Ser at position 164 corresponding to SEQ ID NO 8; and Leu is replaced by Phe at position 28 corresponding to SEQ ID NO 10; or (c) Gly is replaced by Cys at position 268 in SEQ ID NO 12.
[0052] In one specific implementation scheme, the thermophilic streptococcus strain is: (a) DSM 33719 or its mutants or variants; (b) DSM 33720 or its mutants or variants; or (c) DSM 33762 or its mutants or variants.
[0053] Further description of the thermophilic streptococcal strains and the mutations disclosed in (a)-(f) above can be found below, in the section entitled “Novel thermophilic streptococcal mutants”.
[0054] The compositions of the present invention can be provided in a variety of forms. They can be powders, pellets, or tablets. They can be in a frozen, dried, lyophilized, or liquid form. Thus, in one embodiment, the composition is in a frozen, dried, lyophilized, or liquid form.
[0055] The compositions of the present invention may further comprise cryoprotectants, lyophilization protectants, antioxidants, nutrients, fillers, flavorings, or mixtures thereof. The compositions preferably comprise one or more cryoprotectants, lyophilization protectants, antioxidants, and / or nutrients; more preferably, cryoprotectants, lyophilization protectants, and / or antioxidants; and most preferably, cryoprotectants or lyophilization protectants, or both. Protectants known to those skilled in the art, such as cryoprotectants and lyophilization protectants, are used. Suitable cryoprotectants or lyophilization protectants include monosaccharides, disaccharides, trisaccharides, and polysaccharides (e.g., glucose, mannose, xylose, lactose, sucrose, trehalose, raffinose, maltodextrin, starch, and gum arabic), polyols (e.g., erythritol, glycerol, inositol, mannitol, sorbitol, threitol, xylitol, etc.), amino acids (e.g., proline, glutamic acid), complexes (e.g., skim milk, peptone, gelatin, yeast extract), and inorganic compounds (e.g., sodium tripolyphosphate).
[0056] In one embodiment, the composition of the present invention may include one or more cryoprotectants selected from inosine-5'-monophosphate (IMP), adenosine-5'-monophosphate (AMP), guanosine-5'-monophosphate (GMP), uridine-5'-monophosphate (UMP), cytidine-5'-monophosphate (CMP), adenine, guanine, uracil, cytosine, adenosine, guanosine, uridine, cytidine, hypoxanthine, xanthine, hypoxanthine, guanosine, thymidine, inosine, and derivatives of any such compounds. Suitable antioxidants include ascorbic acid, citric acid and its salts, gallate, cysteine, sorbitol, mannitol, and maltose. Suitable nutrients include sugars, amino acids, fatty acids, minerals, trace elements, and vitamins (e.g., B vitamins, vitamin C). The composition may optionally contain other substances, including fillers (e.g., lactose, maltodextrin) and / or flavoring agents.
[0057] In one embodiment of the invention, the cryoprotectant is a reagent or a mixture of reagents that, in addition to its cryoprotective properties, also has an enhancing effect.
[0058] The term "enhancing effect" describes a situation where cryoprotectants confer increased metabolic activity (enhancing effect) upon inoculating thawed or reconstituted cultures into a medium for fermentation or transformation. Viability and metabolic activity are not synonymous. Commercially frozen or lyophilized cultures may retain their viability, but they may have lost a significant portion of their metabolic activity; for example, cultures may lose acid-producing (acidifying) activity within a short storage period. Therefore, viability and enhancing effect must be assessed using different assays. Viability is assessed by viability assays, such as measuring colony-forming units, while enhancing effect is assessed by quantifying the metabolic activity of the thawed or reconstituted culture relative to the viability of the culture. The term "metabolic activity" refers to the culture's deoxygenation activity, its acid-producing activity (i.e., the production of, for example, lactic acid, acetic acid, formic acid, and / or propionic acid), or its metabolite activity (e.g., the production of aromatic compounds such as acetaldehyde, α-acetolactone, acetoin, diacetyl, and 2,3-butanediol).
[0059] In one embodiment, the compositions of the present invention contain or comprise 0.2% to 20% of a cryoprotectant or reagent mixture, measured as a percentage w / w of the material. However, it is preferred to add the cryoprotectant or reagent mixture in amounts of 0.2% to 15%, 0.2% to 10%, 0.5% to 7%, and 1% to 6% by weight, including amounts ranging from 2% to 5% (measured as a percentage w / w of the frozen material). In a preferred embodiment, the culture contains about 3% of a cryoprotectant or reagent mixture, measured as a percentage w / w of the material. About 3% of cryoprotectant corresponds to a concentration in the range of 100 mM. It should be understood that for each aspect of the embodiments of the invention, the range may be an increment of the range.
[0060] In this context, the term "from x% to y%" means including the endpoint, and is therefore equivalent to the term "from x% and including x% to y% and including y%".
[0061] In another aspect, the compositions of the present invention contain or include ammonium salts (e.g., ammonium salts of organic acids (e.g., ammonium formate and ammonium citrate) or ammonium salts of inorganic acids) as enhancers of bacterial cells (e.g., growth enhancers or acidification enhancers), such as cells belonging to the species *Streptococcus thermophilus*, such as (substantial) urease-negative bacterial cells. The terms "ammonium salt," "ammonium formate," etc., should be understood as a source of salt or a combination of ions. For example, the "source" of the terms "ammonium formate" or "ammonium salt" refers to one or a mixture of compounds that provide ammonium formate or an ammonium salt when added to a cell culture. In some embodiments, the ammonium source releases ammonium into the growth medium, while in other embodiments, the ammonium source is metabolized to produce ammonium. In some preferred embodiments, the ammonium source is exogenous. In some particularly preferred embodiments, the ammonium is not provided by a dairy matrix. It should be understood, of course, that ammonia may be added instead of ammonium salts. Therefore, the term ammonium salt includes ammonia (NH3), NH4OH, NH4 + wait.
[0062] In one embodiment, the composition of the present invention may contain thickeners and / or stabilizers, such as pectin (e.g., HM pectin, LM pectin), gelatin, CMC, soy bean fiber / soy bean polymer, starch, modified starch, carrageenan, alginate, and guar gum.
[0063] In one embodiment, microbially produced polysaccharides (e.g., EPS) create a high / viscosity texture in the acidified dairy product, which is substantially free of or completely free of any thickeners and / or stabilizers, such as pectin (e.g., HM pectin, LM pectin), gelatin, CMC, soybean fiber / soybean polymer, starch, modified starch, carrageenan, alginate, and guar gum. "Substantially free" should be understood as meaning the product contains 0% to 20% (by weight) (e.g., 0% to 10%, 0% to 5%, 0% to 2%, or 0% to 1%) of thickeners and / or stabilizers.
[0064] As mentioned earlier, interactions between microbial species are crucial—not only in terms of growth, but also in terms of rheological properties (such as texture) and taste formation.
[0065] In one important embodiment, the composition comprises one or more Streptococcus thermophilus strains selected from the group consisting of: DSM 33719, DSM 33719 mutant, DSM 33719 variant, DSM 33720, DSM 33720 mutant, DSM 33720 variant, DSM 33762, DSM 33762 mutant and DSM 33762 variant.
[0066] In a preferred embodiment, the composition comprises: (a) DSM 33720, DSM 33719 and DSM 33762; (b) DSM 32227 and DSM 33762; or (c) DSM 33719 and DSM 32227.
[0067] As can be seen from Examples 4 and 5, these strain combinations have been tested in terms of the texture and acidification profiles of the fermentation products.
[0068] The composition may be provided as a mixture or as a kit containing: (a) Streptococcus thermophilus strains selected from the group consisting of: DSM 33720 or its mutants or variants, DSM 33719 or its mutants or variants, DSM 33762 or its mutants or variants, or any combination thereof; and (b) Strains belonging to the genus Lactobacillus.
[0069] Therefore, it is conceivable that the composition may be a mixture or as a kit comprising (a) a Streptococcus thermophilus strain containing the following gene mutations: (i) Pro replaced by Leu at position 57 corresponding to SEQ ID NO 2; Ile replaced by Val at position 47 corresponding to SEQ ID NO 4; and Glu replaced by Asp at position 242 corresponding to SEQ ID NO 6 or 14; and / or (ii) Pro replaced by Ser at position 164 corresponding to SEQ ID NO 8; and Leu replaced by Phe at position 28 corresponding to SEQ ID NO 10; and / or (iii) Gly replaced by Cys at position 268 corresponding to SEQ ID NO 12; and (b) one or more strains belonging to the genus Lactobacillus.
[0070] In one embodiment, (i) is DSM 33762 or a mutant or variant thereof, (ii) is DSM 33720 or a mutant or variant thereof, and / or (iii) is DSM 33719 or a mutant or variant thereof.
[0071] If used, for example, in yogurt production, the composition may preferably further comprise one or more strains belonging to the genus *Lactobacillus*. The one or more strains of *Lactobacillus* may be selected from the group consisting of: *Lactobacillus delbrueckii* (…). Lactobacillus delbrueckii Lactobacillus delbrueckii subsp. bulgaricus ( Lactobacillus delbrueckii subsp bulgaricus ) 、 Lactobacillus delbrueckii subsp. lactis ( Lactobacillus delbrueckii subsp. lactis ) 、 Lactobacillus acidophilus ( Lactobacillus acidophilus Lactobacillus casei ( Lacticaseibacillus casei Lactobacillus paracasei subsp. paracasei Lacticaseibacillus paracasei subsp. Paracasei ) and Lactobacillus rhamnosus ( Lacticaseibacillus rhamnosus ) 、 Fermented Lactobacillus mucinus (Limosilactobacillus fermentum), Lactobacillus plantarum subsp. plantarum ( Lactiplantibacillus plantarum subsp . Plantarum ) and Lactobacillus helveticus ( Lactobacillus helveticus ) In a preferred embodiment of the present invention, the Lactobacillus strains are selected from the group consisting of: Lactobacillus delbrueckii subsp. bulgaricus, Lactobacillus plantarum subsp. plantarum, and Lactobacillus acidophilus.
[0072] In one particular embodiment, the lactobacillus strain of the present invention is *Lactobacillus bulgaricus*. *Lactobacillus bulgaricus* is a lactic acid bacterium frequently used in commercial milk fermentation, where the organism is typically used as part of a mixed starter culture.
[0073] In one specific implementation, *Lactobacillus delbrueckii* subsp. bulgaricus is DSM 28910 or a mutant or variant thereof.
[0074] In one embodiment of the invention, the *Lactobacillus* strain of the invention is glucose-deficient. In an alternative embodiment of the invention, the *Lactobacillus* strain of the invention is glucose-positive.
[0075] Therefore, in a preferred embodiment, the composition and / or mixture or kit contains *Streptococcus thermophilus* strains DSM 32227 and / or DSM 33762 and strains belonging to the genus *Lactobacillus*. Therefore, in a preferred embodiment, the composition and / or mixture or kit contains *Streptococcus thermophilus* strains DSM 33719 and / or DSM 32227 and strains belonging to the genus *Lactobacillus*. Therefore, in a preferred embodiment, the composition and / or mixture or kit contains *Streptococcus thermophilus* strain DSM 33720 and strains belonging to the species *Lactobacillus*.
[0076] The compositions of this invention may contain probiotics. The probiotic strains may be added before or after fermentation. If added before fermentation, the probiotic strains also act as fermenting bacteria.
[0077] The term "probiotics" refers to live bacteria administered to consumers in adequate amounts to promote their health. Probiotics can survive in the gastrointestinal tract after ingestion and colonize the consumer's gut.
[0078] It should be understood that the taxonomy of the genus *Lactobacillus* was updated in 2020. The new taxonomy is disclosed in Zheng et al. 2020 and will be used herein unless otherwise indicated. For the purposes of this invention, the following table lists the new and old names of some species of the genus *Lactobacillus* relevant to this invention.
[0079] Table 1. New and old names of some Lactobacillus species related to this invention. In a specific embodiment of the present invention, the probiotic strains of the present invention are selected from bacteria of the genus Lactobacillus, such as Lactobacillus acidophilus and Lactobacillus paracasei. Lacticaseibacillus paracasei Lactobacillus rhamnosus ( Lacticaseibacillus rhamnosu s), Lactobacillus casei ( Lacticaseibacillus casei Lactobacillus delbrueckii (), Lactobacillus delbrueckii Lactobacillus () Lactobacillus lactisLactobacillus plantarum ( Lactiplantibacillus plantarum ), Lactobacillus reuteri ( Limosilactobacillus reuteri ) and Lactobacillus johnsonii ( Lactobacillus johnsonii Bifidobacterium spp. Bifidobacterium ), such as Bifidobacterium longum ( Bifidobacterium longum ), Bifidobacterium adolescentis ( Bifidobacterium adolescentis Bifidobacterium bifidum ( Bifidobacterium bifidum ), Bifidobacterium breve Bifidobacterium breve Bifidobacterium animalis subsp. lactis ( Bifidobacterium animalis subsp. lactis Bifidobacterium densiflorum ( Bifidobacterium dentium ), Bifidobacterium chain Bifidobacterium catenulatum ), Bifidobacterium angularis ( Bifidobacterium angulatum ), Bifidobacterium megaterium ( Bifidobacterium magnum ), Bifidobacterium pseudochain ( Bifidobacterium pseudocatenulatum ) and Bifidobacterium infantis ( Bifidobacterium infantis )wait.
[0080] In a specific embodiment of the present invention, the probiotic lactobacillus strain is selected from Lactobacillus acidophilus, Lactobacillus paracasei, Lactobacillus rhamnosus, Lactobacillus casei, Lactobacillus delbrueckii, Lactobacillus plantarum, Lactobacillus reuteri, and Lactobacillus johnsonii.
[0081] In one specific embodiment of the invention, the probiotic strain is Lactobacillus acidophilus (LA-5) preserved under DSM 13241. ® ).
[0082] In specific embodiments of the present invention, the probiotic Lactobacillus strain is selected from Lactobacillus rhamnosus and Lactobacillus paracasei strains. In specific embodiments of the present invention, the probiotic strain is Lactobacillus rhamnosus strain LGG®, preserved as ATCC 53103. In specific embodiments of the present invention, the probiotic strain is Lactobacillus paracasei strain CRL 431, preserved as ATCC 55544.
[0083] In a specific embodiment of the present invention, the probiotic strain is selected from *Bifidobacterium longum*, *Bifidobacterium adolescentis*, *Bifidobacterium bifidum*, *Bifidobacterium breve*, *Bifidobacterium animalis* subsp. *lactobacterium*, *Bifidobacterium dendriticum*, *Bifidobacterium chainii*, *Bifidobacterium angularis*, *Bifidobacterium megaterium*, *Bifidobacterium pseudochainii*, and *Bifidobacterium infantis*. In a specific embodiment of the present invention, the probiotic strain is *Bifidobacterium animalis* subsp. *lactobacterium* BB-12®, preserved under DSM 15954.
[0084] The above mixtures or kits can be further combined with other lactic acid bacteria, such as, but not limited to, probiotics. In one embodiment, at least one or more lactic acid bacteria are selected from Bifidobacterium, such as Bifidobacterium animalis subsp. lactic acid (e.g., BB-12®), Lactobacillus acidophilus (LA-5®), Lactobacillus rhamnosus (e.g., LGG®), and any combination thereof. The choice of which Bifidobacterium, Lactobacillus acidophilus, and / or Lactobacillus rhamnosus to use depends on the application and the food to be produced.
[0085] In contrast, the term "kit" that includes a bacterial strain refers to a kit where the bacterial strain or bacterial culture is physically separate, but... Figure 1 Therefore, the thermophilic streptococcal strains and lactobacillus strains or cultures are located in separate boxes or pouches. In the embodiments, the thermophilic streptococcal strains and lactobacillus strains, such as Lactobacillus delbrueckii subsp. bulgaricus, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus paracasei, and / or Lactobacillus reuteri strains, are in the same form, i.e., in frozen form, in pellet or frozen pellet form, or in powder form, such as dried powder or lyophilized powder.
[0086] In a specific embodiment of the present invention, the composition comprises 10 4 Up to 10 12 thermophilic streptococcal strains, for example, 10 CFU (colony forming units) / g. 5 Up to 10 11 CFU / g, 10 6 Up to 10 10 CFU / g, or 10 7 Up to 10 9 Thermophilic Streptococcus strains with CFU / g.
[0087] In a specific embodiment, the composition further comprises 10 4 Up to 10 12 Lactobacillus strains with CFU / g, for example, 10 5 Up to 10 11 CFU / g, for example 10 6 Up to 10 10 CFU / g, or for example 10 7 Up to 10 9 Lactobacillus strains with CFU / g.
[0088] In a specific embodiment, the composition comprises 10 μL for each of the following strains: *Lactobacillus delbrueckii* subsp. *bulgaricus*, *Lactobacillus acidophilus*, *Lactobacillus casei*, *Lactobacillus paracasei*, and / or *Mucobacillus reuteri*. 4 Up to 10 12 CFU / g, 10 5 Up to 10 11 CFU / g, 106 Up to 10 10 CFU / g, or 10 7 Up to 10 9 CFU / g.
[0089] In the production of various foods, particularly in the dairy industry, thermophilic streptococci and Lactobacillus species, such as Lactobacillus bulgaricus, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus paracasei, and / or Lactobacillus rhamnosus, as well as other lactic acid bacteria, are commonly used as starter cultures for technical purposes in fermented dairy products. Therefore, in another preferred embodiment, the composition is suitable as a starter culture.
[0090] The composition can be a starter culture, such as a yogurt starter culture.
[0091] The composition and / or starter culture may be frozen, spray-dried, lyophilized, vacuum-dried, air-dried, tray-dried, or in liquid form. Typically, the storage stability of the composition and / or starter culture can be extended by formulating a product with low water activity. By controlling water activity (Aw), the effect of moisture migration on the product can be predicted and adjusted. Therefore, it may be preferred that the water activity (Aw) of the dried compositions described herein ranges from 0.01 to 0.8, preferably from 0.05 to 0.4.
[0092] It is understood that the aspects and embodiments disclosed in the sections entitled "Method for Producing Fermentation Products" and "Novel Thermophilic Streptococcus Strains" are equally relevant to this part of the specification. In particular, the disclosure of specific strains of the invention under "Novel Thermophilic Streptococcus Strains" applies to this part of the specification, as will be clear to those skilled in the art.
[0093] Methods for producing fermented products The term "milk" should be understood as the milk secretion obtained by milking any mammal, such as a cow, sheep, goat, buffalo, or camel. In a preferred embodiment, it is cow's milk.
[0094] The term "milk matrix" can refer to any raw milk and / or processed milk material that can be fermented according to the method of the present invention. Therefore, useful milk matrices include (but are not limited to) solutions / suspensions of any milk or milk-like product containing proteins, such as whole or low-fat milk, skim milk, buttermilk, reconstituted milk powder, condensed milk, dried milk, whey, whey permeate, lactose, mother liquor obtained from lactose crystallization, whey protein concentrate, or milk fat. Obviously, the milk matrix can be derived from any mammal, such as substantially pure mammalian milk, or reconstituted milk powder, or the milk matrix can be partially derived from plant material. Preferably, at least a portion of the proteins in the milk matrix are (i) proteins naturally present in mammalian milk, such as casein or whey protein, or (ii) proteins naturally present in plant milk. However, some proteins may be proteins not naturally present in milk.
[0095] Prior to fermentation, the milk matrix can be homogenized and pasteurized using methods known in the field.
[0096] As used in this article, "homogenization" refers to thorough mixing to obtain a soluble suspension or emulsion. If homogenization is performed before fermentation, this breaks down the milk fat into smaller sizes, preventing it from separating from the milk. This can be achieved by forcing the milk through small pores under high pressure.
[0097] As used herein, "pasteurization" refers to the treatment of a milk matrix to reduce or eliminate the presence of living organisms such as microorganisms. Preferably, pasteurization is achieved by maintaining a specified temperature for a specified period of time. The specified temperature is typically achieved through heating. The temperature and duration can be selected to kill or inactivate certain bacteria, such as harmful bacteria. A rapid cooling step may then be performed.
[0098] Fermentation processes for producing fermented dairy products are well known, and those skilled in the art will understand how to select appropriate process conditions, such as temperature, oxygen, the amount and characteristics of microorganisms, and process time. Clearly, fermentation conditions are selected to support the realization of this invention, i.e., to obtain fermented products, such as dairy products or dairy-like products (fermented dairy products) in solid or liquid form.
[0099] As used herein, the term "fermented dairy product" refers to a food or feed product whose preparation involves fermenting a milk substrate with lactic acid bacteria. "Fermented dairy product" as used herein includes, but is not limited to, products such as yogurt and cheese. Examples of cheeses prepared by fermentation with *Streptococcus thermophilus* and *Lactobacillus delbrueckii* subsp. bulgaricus include mozzarella and pizza cheese (Hoier et al. (2010) in *The Technology of Cheese*, 2). ndEd. Blackwell Publishing, Oxford; 166-192). Preferably, the fermented dairy product is yogurt.
[0100] In this context, the term "fermenting agent" is a culture, which is a preparation (composition) of one or more bacterial strains (such as lactic acid bacteria strains), to assist in the initiation of a fermentation process in the preparation of fermented products such as various foods, feeds, and beverages.
[0101] In this context, "yogurt starter" is a bacterial culture containing one or more strains of the genus *Lactobacillus* selected from *Lactobacillus bulgaricus* and / or *Lactobacillus acidophilus*, and one or more strains of *Streptococcus thermophilus*. Accordingly, "yogurt" refers to a fermented dairy product obtained by inoculating and fermenting a milk substrate with a composition containing, for example, *Lactobacillus bulgaricus* and / or *Lactobacillus acidophilus* strains and *Streptococcus thermophilus* strains.
[0102] Another aspect of the invention relates to a method for producing fermented products, comprising using a fermentation substrate of a Streptococcus thermophilus strain having a mutation in one or more genes selected from the group consisting of: (a) Encoding PTS mannose / glucose / fructose subunit IIC manM The gene is located at position 169 in SEQ ID NO.1; (b) Encoding galactokinase galK The gene is located at position 139 in SEQ ID NO.3; (c) Encoding phosphoglucomutase pgm The gene is located at position 490 corresponding to SEQ ID NO. 5 or 13; (d) Encoding glucose-phosphotransmutase pgm The gene is located at position 726 in SEQ ID NO.7; (e) Encoding galactose operon repressors galR The gene is located at position 82 corresponding to SEQ ID NO.9; and (f) Encoding glucokinase glcK The gene is located at position 805 in SEQ ID NO. 11. Or the composition of the present invention.
[0103] Preferably, the substrate is a milk substrate. The milk substrate can be an animal-derived substrate; however, it need not be purely animal-derived and may further contain plant-derived substrates. The fermented product can be a food or a dairy product.
[0104] Depending on the product to be produced, the substrate can be a milk substrate. A milk substrate is particularly preferred when fermented dairy products such as yogurt, buttermilk, or kefir are finished products.
[0105] The milk matrix can be an animal or plant-derived product. Therefore, in one embodiment, the fermented product is a food, such as a dairy product. Dairy products can be freely selected from the group consisting of: fermented dairy products, such as, but not limited to, yogurt, buttermilk, and kefir, or cheeses, such as, but not limited to, fresh cheese or pastafilata.
[0106] Although fermented products and / or foods themselves contain acids and flavors produced during fermentation, it may be expected that fermented products and / or dairy products contain ingredients selected from the group consisting of: fruit concentrates, syrups, probiotic strains or cultures, colorants, thickeners, flavorings, preservatives, and mixtures thereof.
[0107] Similarly, enzymes can be added to a matrix, such as a milk matrix, before, during, and / or after fermentation. These enzymes are selected from the group consisting of enzymes capable of cross-linking proteins, transglutaminase, aspartic protease, lactase, rennet, and mixtures thereof.
[0108] In one implementation, the fermentation product may be in the form of a stirred product, a coagulated product, or a drinkable product.
[0109] Obviously, another aspect of the present invention relates to fermentation products obtainable by the method of the present invention. Therefore, one aspect of the present invention also includes fermentation products comprising *Streptococcus thermophilus* strains having mutations in one or more genes selected from the group consisting of: (a) Encoding PTS mannose / glucose / fructose subunit IIC manM The gene is located at position 169 in SEQ ID NO.1; (b) Encoding galactokinase galK The gene is located at position 139 in SEQ ID NO.3; (c) Encoding phosphoglucomutase pgm The gene is located at position 490 corresponding to SEQ ID NO. 5 or 13; (d) Encoding glucose-phosphotransmutase pgm The gene is located at position 726 in SEQ ID NO.7; (e) Encoding galactose operon repressors galR The gene is located at position 82 corresponding to SEQ ID NO.9; and (f) Encoding glucokinase glcKThe gene is located at position 805 in SEQ ID NO.11.
[0110] Another aspect of the invention relates to the use of a Streptococcus thermophilus strain in the manufacture of fermentation products, said Streptococcus thermophilus strain having mutations in one or more genes selected from the group consisting of: (a) Encoding PTS mannose / glucose / fructose subunit IIC manM The gene is located at position 169 in SEQ ID NO.1; (b) Encoding galactokinase galK The gene is located at position 139 in SEQ ID NO.3; (c) Encoding phosphoglucomutase pgm The gene is located at position 490 corresponding to SEQ ID NO. 5 or 13; (d) Encoding glucose-phosphotransmutase pgm The gene is located at position 726 in SEQ ID NO.7; (e) Encoding galactose operon repressors galR The gene is located at position 82 corresponding to SEQ ID NO.9; and (f) Encoding glucokinase glcK The gene is located at position 805 corresponding to SEQ ID NO. 11. Similarly, the fermented product can be a food, such as a dairy product or a dairy-like product.
[0111] It should be understood that the aspects and embodiments disclosed in the sections referred to as "Compositions" and "Novel Thermophilic Streptococcus Strains" are equally relevant to this part of the specification. In particular, the disclosure of specific strains of the invention under "Novel Thermophilic Streptococcus Strains" applies to this part of the specification, as will be clear to those skilled in the art.
[0112] Novel thermophilic streptococcal strain The inventors have surprisingly discovered thermophilic streptococcal strains with mutations in one or more genes selected from the following groups: (a) Encoding PTS mannose / glucose / fructose subunit IIC manM The gene is located at position 169 in SEQ ID NO.1; (b) Encoding galactokinase galK The gene is located at position 139 in SEQ ID NO.3; (c) Encoding phosphoglucomutase pgm The gene is located at position 490 corresponding to SEQ ID NO. 5 or 13; (d) Encoding glucose-phosphotransmutase pgm The gene is located at position 726 in SEQ ID NO.7; (e) Encoding galactose operon repressors galR The gene is located at position 82 corresponding to SEQ ID NO.9; and (f) Encoding glucokinase glcK The gene is located at position 805 in SEQ ID NO.11.
[0113] It is conceivable that the *Streptococcus thermophilus* strain contains at least 50% of the same nucleotide sequence as SEQ ID NO: 1, 3, 5, 7, 11 and / or 13. Preferably, the *Streptococcus thermophilus* strain contains at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% of the same nucleotide sequence as SEQ ID NO: 1, 3, 5, 7, 11 and / or 13.
[0114] Therefore, at the amino acid level, it can be further hypothesized that mutations lead to changes in proteins encoded by groups selected from the following: a) PTS mannose / glucose / fructose subunit IIC, at position 57 corresponding to SEQ ID NO 2; b) Galactokinase, at position 47 corresponding to SEQ ID NO 4; c) phosphogluconomutase, at position 242 corresponding to SEQ ID NO 6 or 14; d) phosphogluconomutase, at position 164 corresponding to SEQ ID NO 8; e) The galactose operon repressor, at position 28 corresponding to SEQ ID NO 10; and f) Glucokinase, at position 268 corresponding to SEQ ID NO 12.
[0115] galK The gene encodes galactokinase, an enzyme in the Leloir pathway of galactose metabolism that converts α-galactose into galactose-1-phosphate.
[0116] pgmThe gene encodes phosphoglucomutase, an enzyme that enables a reversible reaction between β-glucose-1-phosphate (G1P) and glucose-6-phosphate (G6P).
[0117] galR The gene encodes a galactosone repressor, which regulates the galactosone in Streptococcus at the transcriptional level.
[0118] In one particular embodiment of the invention, the *Streptococcus thermophilus* strain ferments galactose and encodes a glucokinase protein. glcK The gene carries a mutation in its DNA sequence (more specifically, at position 805 in SEQ ID NO. 11), wherein the mutation inactivates the glucokinase protein or has a negative impact on gene expression.
[0119] In a preferred embodiment, the mutation reduces the activity of the glucokinase protein (the rate at which glucose is phosphorylated to glucose-6-phosphate) by at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%.
[0120] Glucokinase activity can be determined by the enzymatic method of glucokinase as described by Pool et al. (2006. Metabolic Engineering 8;456-464).
[0121] In one particular embodiment of the invention, the *Streptococcus thermophilus* strain carries a mutation that reduces glucose transport into the cell. In another specific embodiment, the *Streptococcus thermophilus* strain carries a gene mutation encoding a component of a glucose transporter, wherein the mutation inactivates the glucose transporter or adversely affects gene expression.
[0122] In a more specific implementation, the *Streptococcus thermophilus* strain encodes the PTS mannose / glucose / fructose subunit IIC. manM The gene carries a mutation in its DNA sequence (also known as IIC of the glucose / mannose phosphotransferase system). Man Proteins (therefore the two are used interchangeably here), wherein the mutation described causes IIC Man The protein is inactivated or has an adverse effect on gene expression. In a preferred embodiment, the mutation reduces glucose transport into the cell by at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% compared to cells without the mutation.
[0123] Glucose transport into cells can be determined by glucose uptake assays as described by Cochu et al. (2003. Appl Environ Microbiol 69(9); 5423-5432).
[0124] Preferably, the Streptococcus thermophilus strain carries a mutation in a gene encoding a component of the glucose transporter, wherein the mutation inactivates the glucose transporter or has an adverse effect on gene expression.
[0125] This component can be any component of a glucose transporter that is essential for glucose transport. For example, it is conceivable that inactivation of any component of the glucose / mannose phosphotransferase system in Streptococcus thermophilus would lead to inactivation of glucose transporter function.
[0126] In particular, an inactivated glucose transporter is a protein that, compared to a functional glucose transporter, fails to promote glucose transport across the plasma membrane or promotes glucose transport across the plasma membrane at a significantly reduced rate. Genes encoding such inactivated glucose transporters, compared to genes encoding functional glucose transporters, include mutations in the gene's open reading frame (ORF), said mutations may include, but are not limited to, deletions, frameshift mutations, the introduction of a stop codon or resulting in amino acid substitutions, mutations altering the functional properties of the protein, or promoter mutations that reduce or eliminate gene transcription or translation.
[0127] In a preferred embodiment, the mutation reduces the activity of the glucose transporter (the rate of glucose transport) by at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%. The glucose transporter activity can be determined by the glucose uptake assay described by Cochu et al. (2003. Appl Environ Microbiol 69(9); 5423-5432).
[0128] In one particular embodiment, when inoculated into 9.5% B milk at a concentration of 1.0E06-1.0E07 CFU / ml and grown at 40°C for 20 hours, the Streptococcus thermophilus strain can increase the glucose content in 9.5% B milk to at least 5 mg / ml.
[0129] In a specific embodiment of the invention, when inoculated into 9.5% B milk containing 0.05% sucrose at a concentration of 1.0E06-1.0E07 CFU / ml and grown at 40°C for 20 hours, Streptococcus thermophilus strains DSM 33719 and / or DSM33762 can increase the glucose content in 9.5% B milk containing 0.05% sucrose to at least 5 mg / ml.
[0130] In this context, 9.5% B milk is a heat-treated milk made from reconstituted low-fat skim milk powder with a dry matter content of 9.5%, pasteurized at 99°C for 30 minutes, and then cooled to 40°C.
[0131] In a more preferred embodiment of the invention, the mutant strain causes the glucose level to increase to at least 4 mg / ml, at least 5 mg / ml, at least 6 mg / ml, at least 7 mg / ml, at least 8 mg / ml, at least 9 mg / ml, at least 10 mg / ml, at least 11 mg / ml, at least 12 mg / ml, at least 13 mg / ml, at least 14 mg / ml, at least 15 mg / ml, at least 20 mg / ml, or at least 25 mg / ml.
[0132] In another embodiment, when inoculated with one or more additional lactic acid bacteria strains at a concentration of 1.0E06-1.0E08 CFU / ml and grown at 40°C for 20 hours, *Streptococcus thermophilus* strains DSM 33719 and / or DSM 33762 can increase the glucose content in a milk base containing 0.1% sucrose, 4% protein (adjusted with skim milk powder), and 1.5% fat (1.5% whole milk adjusted with 9% cream) to at least 5 mg / ml. In a more preferred embodiment of the invention, the glucose content is increased to at least 4 mg / ml, at least 5 mg / ml, at least 6 mg / ml, at least 7 mg / ml, at least 8 mg / ml, at least 9 mg / ml, at least 10 mg / ml, at least 11 mg / ml, at least 12 mg / ml, at least 13 mg / ml, at least 14 mg / ml, at least 15 mg / ml, at least 20 mg / ml, or at least 25 mg / ml.
[0133] The term “mutations that reduce glucose transport into cells” as used in this article refers to mutations in genes encoding proteins involved in glucose transport, which lead to the accumulation of glucose in the cellular environment.
[0134] The glucose level in the culture medium of Streptococcus thermophilus strains can be easily measured using methods known to technicians.
[0135] It is conceivable that the *Streptococcus thermophilus* strain contains at least 50% of the same amino acid sequence as SEQ ID NO: 2, 4, 6, 8, 10 and / or 12. Preferably, the *Streptococcus thermophilus* strain contains at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% of the same nucleotide sequence as SEQ ID NO: 2, 4, 6, 8, 10 and / or 12.
[0136] In a specific implementation plan, the mutation at the nucleic acid level is: (a) Substitution from C to T at position 169 in SEQ ID NO.1; (b) Substitution from G to A at position 139 in SEQ ID NO.3; (c) Substitution from A to C at position 726 corresponding to SEQ ID NO. 5 or 13; (d) Substitution from C to T at position 490 in SEQ ID NO.7; (e) Substitution from C to T at position 82 in SEQ ID NO. 9; and (f) Substitution from G to T at position 805 in SEQ ID NO.11.
[0137] In one specific implementation, the changes to the encoded protein are: (a) Pro is replaced by Leu at position 57 in SEQ ID NO 2; (b) At position 47 in SEQ ID NO 4, Ile is replaced by Val; (c) Glu is replaced by Asp at position 242 in SEQ ID NO 6 or 14; (d) Pro is replaced by Ser at position 164 in SEQ ID NO 8; (e) Leu is replaced by Phe at position 28 in SEQ ID NO 10; and (f) Gly is replaced by Cys at position 268 in SEQ ID NO 12.
[0138] In a preferred embodiment, the thermophilic streptococcal strain includes the following mutations: (d) Substitution from C to T at position 169 in SEQ ID NO.1; substitution from nucleotide G to A at position 139 in SEQ ID NO.3; and substitution from nucleotide A to C at position 726 in SEQ ID NO.5 or 13; (e) A substitution from C to T at position 490 corresponding to position 490 in SEQ ID NO. 5 or 13 and a substitution from nucleotide C to T at position 82 corresponding to position 82 in SEQ ID NO. 7; or (f) Substitution from G to T at position 805 in SEQ ID NO.9.
[0139] In a preferred embodiment, the thermophilic streptococcal strain contains the following variations in the encoded protein: (a) Pro is replaced by Leu at position 57 in SEQ ID NO 2; Ile is replaced by Val at position 47 in SEQ ID NO 4; and Glu is replaced by Asp at position 242 in SEQ ID NO 6 or 14; (b) Pro is replaced by Ser at position 164 corresponding to SEQ ID NO 8; and Leu is replaced by Phe at position 28 corresponding to SEQ ID NO 10; or (c) Gly is replaced by Cys at position 268 in SEQ ID NO 12.
[0140] Table 2. Strains and specific mutations. The identified strain has been deposited. In a preferred embodiment, the present invention relates to *Streptococcus thermophilus* strains: (a) DSM 33719 or its mutants or variants; (b) DSM 33720 or its mutants or variants; or (c) DSM 33762 or its mutants or variants.
[0141] In a preferred embodiment, the present invention relates to Streptococcus thermophilus strain DSM 33719 or its mutants or variants, Streptococcus thermophilus strain DSM 33720 or its mutants or variants, and / or Streptococcus thermophilus strain DSM 33762 or its mutants or variants. In a very preferred embodiment of the invention, the mutants are naturally occurring mutants or induced mutants.
[0142] To ensure industrial applicability, mutants or variants of DSM 33719 are envisioned to exhibit the same or similar characteristics as DSM 33719 (e.g., acidification profiles and texturizing properties). Similarly, mutants or variants of DSM 33720 are envisioned to exhibit the same or similar characteristics as, for example, DSM 33720 (e.g., acidification profiles and texturizing properties). Likewise, mutants or variants of DSM 33719 are envisioned to exhibit the same or similar characteristics as DSM 33719 (e.g., acidification profiles).
[0143] To ensure industrial applicability, mutants or variants of 33719 can be envisioned to exhibit the same or similar characteristics as DSM33719 (e.g., acidification profiles and texturing properties). Similarly, mutants or variants of 33720 can be envisioned to exhibit the same or similar characteristics as, for example, DSM 33720 (e.g., acidification profiles and texturing properties).
[0144] In one embodiment, the mutant or variant strain of DSM 33719 contains at least 50% of the same nucleotide sequence as SEQ ID NO: 1, 3, and / or 5. Preferably, the mutant or variant strain of DSM 33719 contains at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% of the same nucleotide sequence as SEQ ID NO: 1, 3, and / or 5.
[0145] In one embodiment, the DSM 33720 mutant or variant strain of the present invention comprises at least 50% of the same nucleotide sequence as SEQ ID NO: 7 and / or 9. Preferably, the DSM 33720 mutant or variant strain comprises at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% of the same nucleotide sequence as SEQ ID NO: 7 and / or 9.
[0146] In one embodiment, the mutant or variant strain of DSM 33762 contains at least 50% of the same nucleotide sequence as SEQ ID NO: 11. Preferably, the mutant or variant strain of DSM 33762 contains at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% of the same nucleotide sequence as SEQ ID NO: 11.
[0147] In one embodiment, the mutant or variant strain of DSM 33719 contains at least 50% of the same amino acid sequence as SEQ ID NO: 1, 3, and / or 5. Preferably, the mutant or variant strain of DSM 33719 contains at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% of the same amino acid sequence as SEQ ID NO: 1, 3, and / or 5.
[0148] In one embodiment, the DSM 33720 mutant or variant strain of the present invention contains at least 50% of the same amino acid sequence as SEQ ID NO: 7 and / or 9. Preferably, the DSM 33720 mutant or variant strain contains at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% of the same amino acid sequence as SEQ ID NO: 7 and / or 9.
[0149] In one embodiment, the mutant or variant strain of DSM 33762 contains at least 50% of the same amino acid sequence as SEQ ID NO: 11. Preferably, the mutant or variant strain of DSM 33762 contains at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% of the same amino acid sequence as SEQ ID NO: 11.
[0150] As previously mentioned, the industry needs to develop novel thermophilic streptococcal strains with sweetness properties. Therefore, in a preferred embodiment, the thermophilic streptococcal strain according to the invention is galactose-fermenting.
[0151] In this context, the term "fermented galactose" as defined herein refers to galactose fermented at a concentration of at least 10... 4 Inoculate at a rate of 10 cells / ml and incubate in M17 containing 2% galactose (galactose added as the sole carbohydrate) at 37°C for 16 hours until the pH decreases by at least 1.0.
[0152] Some bacterial strains can ferment both galactose and glucose—DSM 33720 is one such example, as it can ferment both. DSM 33720 carries a mutation that prevents or limits glucose transport out of the cell. Therefore, the accumulation of glucose in the fermentation products differs from other galactose-fermenting strains. Consequently, DSM 33720 is a strain with a mildly sweet taste.
[0153] Terms such as “strain with sweetness characteristics”, “strain capable of providing the desired glucose accumulation in fermented dairy products” and “strain with properties that enhance the natural sweetness of food” are used interchangeably herein to characterize the advantages of using the strains of the present invention in dairy product fermentation.
[0154] In one embodiment of the invention, when a fermentation product prepared by adding a composition (mixed culture) of DSM 33720, DMS 33762 and / or DSM 33719 and one or more other lactic acid bacteria strains is measured, the thermophilic streptococcal strains DSM 33720, DMS 33762 and / or DSM 33719 show a 300 s response time. -1 Stresses greater than 45 Pa, 50 Pa, 60 Pa, 70 Pa, 80 Pa, 90 Pa, or 100 Pa are generated. This is likely desirable because it resembles the viscosity / texture thickness preferred by the sensory panel. Shear stress is measured as described in Example 4.
[0155] It is conceivable that the *Streptococcus thermophilus* strain of the present invention is 2-deoxyglucose resistant. The term "2-deoxyglucose resistant" in relation to *Streptococcus thermophilus* is defined herein as the ability of a specific mutant bacterial strain to grow into colonies when streaked on an M17 medium containing 20 mM 2-deoxyglucose after incubation at 40°C for 20 hours. The presence of 2-deoxyglucose in the medium will inhibit the growth of non-mutant strains, while the growth of mutant strains will be unaffected or minimally affected. Therefore, 2-deoxyglucose can be used in selection processes for selection purposes.
[0156] In one implementation, the thermophilic streptococcal strain DSM 33720 carries a mutation that enables the strain to highly ferment galactose.
[0157] It should be understood that the aspects and embodiments disclosed in the sections entitled "Composition" and "Method for producing fermentation products" are equally relevant to this part of the specification.
[0158] In the context of describing this invention, the terms “a” and “the” and similar pronouns should be interpreted as encompassing both singular and plural, unless otherwise stated herein or obviously contradicted by the context. Unless otherwise stated, the terms “comprising,” “having,” “including,” and “containing” should be interpreted as open-ended terms (i.e., meaning “including, but not limited to,”). Unless otherwise stated herein, descriptions of numerical ranges are intended only as a way of abbreviating each individual value within the range, and each individual value is incorporated into the specification as if it were described separately herein. Unless otherwise stated herein or obviously contradicted by the context, all methods described herein may be performed in any suitable order. The use of any and all embodiments or exemplary language (e.g., “such as”) provided herein is intended only to better illustrate the invention and not to limit the scope of the invention, unless otherwise required. No language in the specification should be construed as indicating that any unclaimed element is essential to the practice of the invention.
[0159] Any enumeration or discussion of documents that are obviously previously published in this specification shall not necessarily be construed as an admission that such documents are part of the prior art or common general knowledge.
[0160] Unless the context otherwise indicates, preferred, selected, and embodiments of a given aspect, feature, or parameter of the invention should be considered as having been disclosed in combination with any and all preferred, selected, and embodiments of the invention incorporating all other aspects, features, and parameters of the invention. This is especially true for the description of fat-encapsulated microbial cultures and all their characteristics, which may already be part of a final composition or finished product obtained by the methods described herein. Embodiments and features of the invention are also outlined in the following items.
[0161] Preservation and expert solutions The applicant requires that, prior to the patent grant date, the preserved microbial samples described in the table below may only be provided to professionals.
[0162] Table 3. Depository at institutions that have obtained international depository status under the Budapest Treaty on the International Recognition of the Preservation of Microorganisms for Patent Proceedings: Leibniz Institute DSMZ - German Collection of Microorganisms and Cell Cultures, Inhoffenstr. 7B, 38124 Braunschweig, Germany. Example Materials and methods Table 4. Composition of the culture medium, amount of each component per liter of H2O Aseptically added carbon source: Lactose 20 g / L Glucose 20 g / L, 25 g / L or 50 g / L Galactose 20 g / l, 25 g / l or 50 g / l.
[0163] As is known in the art, M17 medium is considered suitable for the growth of Streptococcus thermophilus. In this context, those skilled in the art understand that M17 concentrate can be supplied by different vendors without dependence on a specific vendor. Individuals will obtain the 2-deoxyglucose resistance results relevant to this paper (within the scope of measurement uncertainty) for the same cells of interest described herein.
[0164] Streptococcus thermophilus strain DSM 33762 is a 2-deoxyglucose-resistant mutant, while DSM 33720 is a strain that highly ferments galactose; both are derived from the same galactosomal yeast strain (MS-1).
[0165] DSM 33719 is a rapidly glucose-secreting strain derived from a high-lactose fermentation and glucose-secreting mother strain (MS-2).
[0166] Lactic acidification curves and carbohydrate analysis B-milk was used as the base. B-milk consisted of skim milk powder with a dry matter content of 9.5% (w / v), which was reconstituted in distilled water, pasteurized at 99°C for 30 minutes, and then cooled to 30°C.
[0167] Acidification is then performed using existing CINAC hardware and software or the ICINC system (AMS alliance). This system is designed to monitor the acidification activity of lactic acid fermentation products and can simultaneously track and record changes in pH and temperature using electrodes.
[0168] The carbohydrate content was analyzed using HPLC. Equal portions of the acidified B-milk were collected after acidification at 40°C for approximately 20 hours. Carbohydrate content is expressed in g / L.
[0169] Example 1 - Separation of thermophilic streptococcal glucokinase mutations with increased glucose excretion using 2-deoxyglucose strain.
[0170] To isolate the mutant strain, MS-1 cells derived from single-colony growth were inoculated into 10 ml of M17 broth containing 2% lactose and grown overnight at 40°C.
[0171] The following day, serial dilutions of the culture were plated on M17 agar plates containing 2% galactose and 30 mM 2-deoxyglucose and incubated at 40°C for 20 hours. Resistant colonies were first re-stripered on the same type of agar plates used for selection. Surviving colonies were inoculated with fresh M17 broth containing 2% lactose, 2% galactose, or 2% glucose, and growth was measured. Among the selected mutants, DSM 33762 was identified. This isolate secretes glucose upon growth in milk (…). Figure 1 Furthermore, genome sequencing identified a gene mutation encoding glucokinase.
[0172] from Figure 1 It is evident that DSM 33762 exhibits a slower acidification curve compared to MS-1. Furthermore, carbohydrate analysis of DSM33762 revealed a decrease in lactose content and an increase in both galactose and glucose secretion compared to fermented milk prepared via MS-1.
[0173] Example 2 - Using adaptive laboratory evolution to isolate organisms with faster growth on galactose-containing media A rate-dependent thermophilic streptococcal mutant.
[0174] Adaptive laboratory evolution (ALE) is used to produce mutant strains that ferment galactose and exhibit a faster growth rate in media with galactose as the sole sugar source compared to their parent strains.
[0175] ALE was performed using three replicates of MS-1 cultures grown for 4 weeks in M17 medium containing 5% galactose and 2% casein hydrolysate. ALE was based primarily on methods employed by Troy E. Sandberg, Michael J. Salazar, Liam L. Weng, Bernhard O. Palsson, and Adam M. Feist. The emergence of adaptive laboratory evolution as an efficient tool for biological discovery and industrial biotechnology The scheme was carried out according to the protocol described in Metabolic Engineering, Volume 56, 2019, Pages 1-16 (Sandberg et al. 2019).
[0176] Growth rate improvement tests were performed weekly on the adapted cultures. This was done by directly testing aliquots of the adapted cultures in the same medium used for the ALE process, and also by plated dilutions of the adapted cultures on M17 agar plates containing galactose. Single colonies from these plates were purified, and the optimized performance was then tested in M17 medium containing galactose + casein hydrolysate. Most isolates showed significantly improved growth rates compared to MS-1. DSM 33720 was isolated after 3 weeks of ALE.
[0177] DSM 33720 was found to exhibit excellent texturization properties in milk and a rapid acidification rate. Figure 2 ).
[0178] Example 3 - Using adaptive laboratory evolution to isolate organisms with faster growth rates on galactose and lactose-containing media A long-rate glucose-secreting Streptococcus thermophilus mutant.
[0179] As described in WO2013 / 160413, MS-2 is a strain with high glucose secretion due to a double mutation (glcK, Glu / Man PTS). However, this mutant strain typically exhibits slower performance in milk, and therefore ALE was used to isolate a faster derivative for this purpose. Three replicate MS-2 cultures were grown for 3 weeks in M17 medium containing 5% galactose + 2% casein hydrolysate. In week 4, the medium was changed to M17 medium containing 2.5% galactose + 2.5% lactose + 2% casein hydrolysate. ALE was performed according to essentially the protocol described in Sandberg et al. 2019.
[0180] Figure 3The figure represents the entire 4-week growth process, during which the culture was diluted and regrowthed daily or several times a day until faster growth was achieved. Starting with a low initial growth rate, the growth rate increased significantly after 4 weeks. After 4 weeks, diluted cultures from every 3 parallel cultures were plated, and single colonies were picked from these agar plates. DSM 33719 is from... Figure 3 One such isolate is shown in the medium gray curve (culture 3).
[0181] Figure 4 Results for DSM 33719 are shown. Compared to MS-2, DSM 33719 acidified much faster and to a lower pH. Carbohydrate analysis of the fermented milk provides an indication of why DSM 33719 was faster. Glucose secretion was reduced by half, and DSM 33719 was also observed to be well-suited for growth on peptides (casein hydrolysate). Further analysis of DSM 33719 revealed that, in addition to exhibiting faster acidification, particularly with the addition of casein hydrolysate or pre-culture, it also provided improved texture to the milk when DSM 33719 was part of a mixed culture (see Example 4).
[0182] Example 4 - Acidification and carbohydrate analysis of milk fermented with different combinations and proportions of bacterial strains.
[0183] Table 5. Strain Combinations for Cultures Yogurt cultures Premium 1.0 and YF-L904, sold by Chr. Hansen, are included as references.
[0184] Two different milk bases were produced before fermentation. Skim milk powder and sucrose were added to the milk, followed by hydration for 2 hours without stirring, then homogenization and pasteurization at >=80°C for 1 minute.
[0185] Milk base 1 contains 0.1% sucrose, 4% protein (adjusted with skim milk powder), and 1.5% fat (1.5% whole milk adjusted with 9% cream). Milk base 2 contains 5% sucrose, 4% protein (adjusted with skim milk powder), and 1.5% fat (1.5% whole milk adjusted with 9% cream).
[0186] Transfer the emulsion base to a 200 mL baby bottle. Inoculate the bottle with a 100-fold dilution prepared by dissolving frozen pellets (F-DVS) in emulsion B. Prepare a separate dilution for each strain. To generate a mixture, several strains were inoculated into one CINAC bottle at different proportions and volumes. The final inoculation rate of the mixture was 1E+6–1E+8 CFU / mL.
[0187] Except for DSM 33762 used in Culture 2, all strains were inoculated from the first dilution produced by F-DVS. To prepare DSM 33762 inoculum, a small amount of DSM 33762 was inoculated into 1 mL of M-17 BK medium containing 4% sucrose and excess casein peptone, and incubated at 43°C for at least 18 hours.
[0188] Place the inoculated bottles in a water bath and heat to 43°C.
[0189] According to existing technology, the pH was monitored at 43°C using CINAC hardware and software until the mixture reached a final pH of 4.55. To obtain a homogeneous fermented milk gel, each bottle was stirred and processed in a microapplication platform (MAP) at 25°C and 2 bar. This MAP is a small laboratory device comparable to existing post-processing units (PTUs) used in dairy farms.
[0190] Prepare a fermented milk sample by weighing 1 g + / - 0.5 g into a 10 mL centrifuge tube and performing carbohydrate analysis using HPLC. Add 2 mL of ice-cold 96% ethanol, vortex the sample, and incubate at -50°C until HPLC analysis is complete.
[0191] Prior to texture analysis (rheology), baby bottles containing fermented milk samples were stored at 5°C for 7 days. For rheological measurements, the samples were transferred to bob cups and shear stress was analyzed.
[0192] Shear stress was measured using an Anton Paar ASC DSR502 rheometer. The method employed a rotational step based on the sample's rotational deformation from 10⁻³ s⁻¹ to 300 s⁻¹ and back to 10⁻³ s⁻¹. The corresponding shear stress was measured. For these results, a shear rate (300 s⁻¹) was extracted from the flow curve. Before measurement, the samples were placed at 13°C for 1 hour. Each sample was gently stirred 5 times from bottom to top with a small spoon to ensure homogeneity. The rheology cups were filled to the line and then placed in the sample magazine. Two separate yogurt cups were used to measure the samples, in duplicate. Measurements were performed on day +7, with the measurement temperature set at 13°C. The samples were stored at 5°C until the day of measurement.
[0193] Table 6. Fermentation time, texture, and glucose levels obtained using culture 1, culture 3, and culture 4. The experiment was conducted on culture 1. The results for cultures 3 and 4 were obtained from different mixtures, i.e., for example, each of the eight mixtures of culture 3 contained the same strain, but in different amounts and proportions.
[0194] Fermentation time, texture, and glucose levels depend on the culture / mixture. Cultures 3 and 4 provided textures as good as the optimally textured culture Premium 1.0, while culture 1 provided a much lower texture in fermented dairy products. Different proportions of strains in blend variants can lead to variations in, for example, fermentation time, texture, or glucose levels. Therefore, the composition of cultures and mixtures can be adjusted accordingly to meet the specific requirements of the final fermented product.
[0195] Table 7. Fermentation time, texture, and glucose levels obtained using culture 1 and culture 2. The table above shows the results obtained using Culture 1 and Culture 2 (mixtures 1-6). Mixtures 1-6 are six mixture variations containing the same strain but in different amounts and proportions. It can be seen that Culture 2 produces similar textures in both emulsion media compared to Culture 1. Simultaneously, Culture 2 results in shorter fermentation times and lower glucose levels.
[0196] Example 5 - Changes in the proportion of bacterial strains in the mixture altered the properties of the fermented dairy product. Fermented milk was produced and analyzed as described in Example 4.
[0197] Table 8. Composition of mixed variations in culture 4 (percentage of total) Table 9. Fermentation time, texture and glucose level of the mixed variants of culture 4 obtained in milk-based 1. Table 10. Fermentation time, texture and glucose levels of the mixed variants of culture 4 obtained in milk-based 2. The varying proportions of strains in the mixed variants of culture 4 (S03b, S03, and P07) resulted in variations in fermentation time, texture (shear stress at 300 × s), and glucose levels. In milk bases 1 and 2, the mixed variants exhibited better texture compared to culture 1. In milk base 2, the mixed variants of culture 4 showed faster fermentation compared to culture 1. Therefore, the characteristics of the culture / mixture are determined by the properties and abundance of each strain, resulting in different fermentation products. The composition of the culture and mixture can be adjusted accordingly to meet the specific requirements of the final fermentation product.
[0198] project Project Y1. A composition comprising a thermophilic streptococcal strain having a mutation in one or more genes selected from the group consisting of: (a) Encoding PTS mannose / glucose / fructose subunit IIC manM The gene is located at position 169 in SEQ ID NO.1; (b) Encoding galactokinase galK The gene is located at position 139 in SEQ ID NO.3; (c) Encoding phosphoglucomutase pgm The gene is located at position 490 corresponding to SEQ ID NO. 5 or 13; (d) Encoding glucose-phosphotransmutase pgm The gene is located at position 726 in SEQ ID NO.7; (e) Encoding galactose operon repressors galR The gene is located at position 82 corresponding to SEQ ID NO.9; and (f) Encoding glucokinase glcK The gene is located at position 805 in SEQ ID NO.11.
[0199] Project Y2. The composition according to Project Y1, wherein the mutation results in a change in the protein encoded by a selection from the group consisting of: a) PTS mannose / glucose / fructose subunit IIC, at position 57 corresponding to SEQ ID NO 2; b) Galactokinase, at position 47 corresponding to SEQ ID NO 4; c) phosphogluconomutase, at position 242 corresponding to SEQ ID NO 6 or 14; d) phosphogluconomutase, at position 164 corresponding to SEQ ID NO 8; e) The galactose operon repressor, at position 28 corresponding to SEQ ID NO 10; and f) Glucokinase, at position 268 corresponding to SEQ ID NO 12.
[0200] Project Y3. The composition according to any one of the preceding projects, wherein the mutation is: (a) Substitution from C to T at position 169 in SEQ ID NO.1; (b) Substitution from G to A at position 139 in SEQ ID NO.3; (c) Substitution from A to C at position 726 corresponding to SEQ ID NO. 5 or 13; (d) Substitution from C to T at position 490 in SEQ ID NO.7; (e) Substitution from C to T at position 82 in SEQ ID NO. 9; and (f) Substitution from G to T at position 805 in SEQ ID NO.11.
[0201] Project Y4. The composition according to any one of the preceding projects, wherein the variation of the encoded protein is: (a) Pro is replaced by Leu at position 57 in SEQ ID NO 2; (b) At position 47 in SEQ ID NO 4, Ile is replaced by Val; (c) Glu is replaced by Asp at position 242 in SEQ ID NO 6 or 14; (d) Pro is replaced by Ser at position 164 in SEQ ID NO 8; (e) Leu is replaced by Phe at position 28 in SEQ ID NO 10; and (f) Gly is replaced by Cys at position 268 in SEQ ID NO 12.
[0202] Project Y5. The composition according to any one of the preceding projects, wherein the thermophilic streptococcal strain contains the following mutation: (a) Substitution from C to T at position 169 in SEQ ID NO.1; substitution from nucleotide G to A at position 139 in SEQ ID NO.3; and substitution from nucleotide A to C at position 726 in SEQ ID NO.5 or 13; (b) A substitution from C to T at position 490 corresponding to position 490 in SEQ ID NO. 5 or 13 and a substitution from nucleotide C to T at position 82 corresponding to position 82 in SEQ ID NO. 7; or (c) Substitution from G to T at position 805 in SEQ ID NO.9.
[0203] Project Y6. The composition according to any one of the preceding projects, wherein the Streptococcus thermophilus strain comprises the following variations of the encoded protein: (a) Pro is replaced by Leu at position 57 in SEQ ID NO 2; Ile is replaced by Val at position 47 in SEQ ID NO 4; and Glu is replaced by Asp at position 242 in SEQ ID NO 6 or 14; (b) Pro is replaced by Ser at position 164 corresponding to SEQ ID NO 8; and Leu is replaced by Phe at position 28 corresponding to SEQ ID NO 10; or (c) Gly is replaced by Cys at position 268 in SEQ ID NO 12.
[0204] Project Y7. The composition according to any one of the preceding projects, wherein the thermophilic streptococcal strain is: (a) DSM 33719 or its mutants or variants; (b) DSM 33720 or its mutants or variants; or (c) DSM 33762 or its mutants or variants.
[0205] Project Y8. The composition according to any one of the preceding projects, wherein the composition comprises one or more Streptococcus thermophilus strains selected from the group consisting of: DSM 33719, DSM 33719 mutant, DSM 33719 variant, DSM 33720, DSM 33720 mutant, DSM 33720 variant, DSM 33762, DSM 33762 mutant and DSM33762 variant.
[0206] Project Y9. The composition according to the foregoing project, wherein the composition comprises: (a) DSM 33720, DSM 33719 and DSM 33762; (b) DSM 32227 and DSM 33762; or (c) DSM 33719 and DSM 32227.
[0207] Project Y10. The composition according to any one of the preceding projects further comprises one or more strains belonging to the genus Lactobacillus.
[0208] Project Y11. The composition according to Project Y10, wherein the strain of one or more of the Lactobacillus species is selected from the group consisting of: Lactobacillus delbrueckii, Lactobacillus delbrueckii subsp. bulgaricus, Lactobacillus delbrueckii subsp. lactis, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus paracasei subsp. casei and Lactobacillus rhamnosus, Lactobacillus fermentum, Lactobacillus plantarum subsp. plantarum and Lactobacillus helveticus.
[0209] Project Y12. The composition according to any one of Y9-Y10, wherein the Lactobacillus delbrueckii subsp. bulgaricus is DSM 28910 or a mutant or variant thereof.
[0210] Project Y13. The composition according to any one of the preceding projects, comprising, in the form of a mixture or a kit: (a) Streptococcus thermophilus strains selected from the group consisting of: DSM 33720 or its mutants or variants, DSM 33719 or its mutants or variants, DSM 33762 or its mutants or variants, or any combination thereof; and (b) Strains belonging to the genus Lactobacillus.
[0211] Project Y14. The composition according to any one of the preceding projects, wherein the composition is a fermentation agent.
[0212] Item Y15. The composition according to any one of the preceding items, wherein the composition is in the form of freeze-dried, spray-dried, freeze-dried, vacuum-dried, air-dried, tray-dried, or liquid.
[0213] Project Z1. A method for producing a fermentation product, comprising fermenting a substrate with a Streptococcus thermophilus strain, said Streptococcus thermophilus strain having a mutation in one or more genes selected from the group consisting of (a)-(f) of Project Z1.
[0214] Project Z2. The method according to Project Z1, wherein the matrix is an emulsion matrix.
[0215] Project Z3. The method according to any one of Projects Z1-Z2, wherein the milk matrix is derived from an animal.
[0216] Project Z4. The method according to any one of Projects Z1-Z3, wherein the milk matrix further comprises a plant-derived matrix.
[0217] Project Z5. The method according to any one of Projects Z1-Z4, wherein the fermented product is a food product.
[0218] Project Z6. The method according to any one of Projects Z1-Z3, wherein the food is a dairy product.
[0219] Project Z7. The method according to Project Z6, wherein the dairy product is selected from the group consisting of: fermented dairy products (e.g., yogurt, buttermilk, or kefir) or cheese (e.g., fresh cheese or pastafilata).
[0220] Project Z8. The method according to any one of Projects Z1-Z7, wherein the fermented product further comprises an ingredient selected from the group consisting of: fruit concentrate, syrup, probiotic strains or cultures, coloring agents, thickeners, flavoring agents, preservatives, and mixtures thereof.
[0221] Project Z9. The method according to Project Z8, wherein an enzyme is added to the substrate before, during and / or after fermentation, said enzyme being selected from the group consisting of: enzymes capable of cross-linking proteins, transglutaminase, aspartic protease, rennet, abomasin, lactase and combinations thereof.
[0222] Project Z10. The method according to any one of Projects Z1-Z9, wherein the fermentation product is in the form of a stirred product, a coagulated product, or a drinkable product.
[0223] Project Q1. A fermentation product obtainable by any one of Projects Z1-Z10.
[0224] Project Q2. The fermented product described in Project Q1, wherein the fermented product is a food product.
[0225] Item Q3. Fermented products according to any one of Items Q1-Q2, wherein the food is a dairy product.
[0226] Project P1. A fermentation product comprising one or more strains of Streptococcus thermophilus with mutations in one or more genes selected from the group consisting of (a)-(f) of Project Y1.
[0227] Project P2. Fermented products as described in Project P1, wherein the fermented products are food products.
[0228] Project P3. Fermented products according to Project P1, wherein the food is a dairy product.
[0229] Project W1. Use of one or more thermophilic streptococcal strains having mutations in one or more genes selected from the group consisting of (a)-(f) of project Y1 to produce fermentation products.
[0230] Project W2. As described in requirement W1, wherein the fermented product is a food product.
[0231] Project W3. Use according to any one of W1-W2, wherein the food is a dairy product.
[0232] Project X1. A thermophilic streptococcal strain with a mutation in one or more genes selected from the group consisting of (a)-(f) of project Y1.
[0233] Item X3. A thermophilic streptococcal strain according to any one of items X1-X2, wherein the thermophilic streptococcal strain is a galactose-fermenting strain.
[0234] Item X4. A thermophilic streptococcal strain according to any one of items X1-X3, wherein the thermophilic streptococcal strain is 2-deoxyglucose resistant.
[0235] Item X5. A Streptococcus thermophilus strain according to any one of Items X1-X4, wherein the Streptococcus thermophilus carries a mutation that reduces glucose transport into the cell.
[0236] 6. The Streptococcus thermophilus strain according to any one of items X1-X5, wherein when inoculated into 9.5% B milk at a concentration of 1.0E06-1.0E07 CFU / ml and grown at 40°C for 20 hours, the Streptococcus thermophilus increases the amount of glucose in the 9.5% B milk to at least 5 mg / ml.
[0237] Item X7. The Streptococcus thermophilus strain according to any one of Items X1-X6, wherein when inoculated into 9.5% B milk containing 0.05% sucrose at a concentration of 1.0E06-1.0E07 CFU / ml and grown at 40°C for 20 hours, the Streptococcus thermophilus strain increases the glucose content in the 9.5% B milk containing 0.05% sucrose to at least 5 mg / ml.
[0238] sequence list SEQ ID NO 1: Encoding PTS mannose / glucose / fructose subunit IIC manM Gene-nucleotide sequence.
[0239] SEQ ID NO 2: PTS mannose / glucose / fructose subunit IIC ( ManM )-amino acid sequence.
[0240] SEQ ID NO 3: Encoding galactokinase galK - Nucleotide sequence.
[0241] SEQ ID NO 4: Galactokinase ( GalK )-amino acid sequence.
[0242] SEQ ID NO 5: Encoding glucose-phosphotransmutase pgm - Nucleotide sequence.
[0243] SEQ ID NO 6: phosphoglucopolysaccharide (PQP) Pgm )-amino acid sequence.
[0244] SEQ ID NO 7: Encoding glucose-phosphotransmutase pgm - Nucleotide sequence.
[0245] SEQ ID NO 8: phosphoglucopolysaccharide (PQP) Pgm )-amino acid sequence.
[0246] SEQ ID NO 9: Encoding galactose operon repressor galR - Nucleotide sequence.
[0247] SEQ ID NO 10: Galactose operon repressor ( GalR )-amino acid sequence.
[0248] SEQ ID NO 11: Encoding glucokinase glcK - Nucleotide sequence.
[0249] SEQ ID NO 12: Glucokinase (GlcK) - amino acid sequence.
[0250] SEQ ID NO 13: pgm-nucleotide sequence encoding phosphoglucose mutase.
[0251] SEQ ID NO 14: Phosphoglucose mutase ( Pgm )-amino acid sequence.
Claims
1. A composition comprising Streptococcus thermophilus (Streptococcus thermophilus) Streptococcus thermophilus ) strain DSM 33720.
2. The composition according to claim 1 further comprises Streptococcus thermophilus strains DSM 33719 and / or DSM 33762.
3. The composition according to claim 1 or 2, further comprising one or more species belonging to the genus *Lactobacillus* (…). Lactobacillus The strain of Lactobacillus, wherein the strain of Lactobacillus is selected from Lactobacillus delbrueckii ( Lactobacillus delbrueckii Lactobacillus delbrueckii subsp. bulgaricus ( Lactobacillus delbrueckii subsp bulgaricus ) 、 Lactobacillus delbrueckii subsp. lactis ( Lactobacillus delbrueckii subsp. lactis ) 、 Lactobacillus acidophilus ( Lactobacillus acidophilus Lactobacillus casei ( Lacticaseibacillus casei Lactobacillus paracasei subsp. paracasei Lacticaseibacillus paracasei subsp. Paracasei Lactobacillus rhamnosus ( Lacticaseibacillus rhamnosus ) 、 Fermented Lactobacillus mucinus (Limosilactobacillus fermentum) Lactobacillus plantarum subsp. plantarum ( Lactiplantibacillus plantarum subsp . Plantarum ) and Lactobacillus helveticus ( Lactobacillus helveticus ).
4. A complete reagent kit, comprising: (a) Streptococcus thermophilus strain DSM 33720; and (b) A strain belonging to the genus *Lactobacillus*, wherein the strain is selected from *Lactobacillus delbrueckii* (…). Lactobacillus delbrueckii Lactobacillus delbrueckii subsp. bulgaricus ( Lactobacillus delbrueckii subsp bulgaricus ) 、 Lactobacillus delbrueckii subsp. lactis ( Lactobacillus delbrueckii subsp. lactis ) 、 Lactobacillus acidophilus ( Lactobacillus acidophilus Lactobacillus casei ( Lacticaseibacillus casei Lactobacillus paracasei subsp. paracasei Lacticaseibacillus paracasei subsp. Paracasei Lactobacillus rhamnosus ( Lacticaseibacillus rhamnosus ) 、 Fermented Lactobacillus mucinus (Limosilactobacillus fermentum) Lactobacillus plantarum subsp. plantarum ( Lactiplantibacillus plantarum subsp . Plantarum ) and Lactobacillus helveticus ( Lactobacillus helveticus ).
5. The kit according to claim 4, wherein component (a) further comprises Streptococcus thermophilus strains DSM33719 and / or DSM 33762.
6. A method for producing a fermented product, comprising using a fermented milk substrate of Streptococcus thermophilus strain DSM 33720.
7. The method of claim 6 further comprises using a fermented milk substrate of Streptococcus thermophilus strain DSM 33719 and / or DSM 33762.
8. A fermentation product obtained by the method according to claim 6 or 7.
9. Use of Streptococcus thermophilus strain DSM 33720 in the manufacture of fermented milk products.
10. The use according to claim 9 further includes the use of Streptococcus thermophilus strains DSM 33719 and / or DSM33762 in the manufacture of fermented milk products.
11. A thermophilic streptococcal strain, wherein the thermophilic streptococcal strain is DSM 33720.
Citation Information
Patent Citations
Lactic bacterium with modified galactokinase expression for texturizing food products by overexpression of exopolysaccharide
WO2011026863A1
Use of lactic acid bacteria for preparing fermented food products with increased natural sweetness
WO2013160413A1
Use of lactic acid bacteria for preparing fermented food products with increased natural sweetness
CN104254600A
Lactic acid bacteria for preparing fermented food products with increased natural sweetness and high texture
CN108777970A
